Table 1.
Characteristics of female patients with systemic lupus erythematosus.
| Variable | Mean ± SD or n (%) |
|---|---|
| Number, n | 155 |
| Age, yr | 53.7 ± 6.8 |
| Postmenopausal status, n (%) | 113 (72.9) |
| Current smoking, n (%) | 2 (1.3) |
| Alcohol > 3 units/day, n (%) | 9 (45.8) |
| Weight, kg | 55.4 ± 9.2 |
| Height, cm | 156.6 ± 5.8 |
| Body mass index, kg/m2 | 22.6 ± 3.6 |
| Disease duration, months | 47.2 ± 8.0 |
| Oral ulcer, n (%) | 20 (12.9) |
| Skin rash, n (%) | 21 (13.5) |
| Arthritis, n (%) | 91 (58.7) |
| Nephritis, n (%) | 20 (12.9) |
| Serositis, n (%) | 9 (5.8) |
| Hematologic involvement, n (%) | 31 (20) |
| Anti-dsDNA (+), n (%) | 37 (23.9) |
| Low complements level, n (%) | 47 (30.3) |
| ESR, mm/hr | 21.7 ± 1.5 |
| SLEDAI | 3.5 ± 0.3 |
| Hydroxychloroquine, n (%) | 141 (91) |
| Glucocorticoids cumulative dose, g | 8.7 ± 0.8 |
| Glucocorticoids current dose, mg/d | 3.4 ± 0.5 |
| Immunosuppressants, n (%) | 66 (42.6) |
| Osteoporosis therapy, n (%) | 48 (31) |
| Duration of osteoporosis therapy, years | 2 (1–4)a |
| Bisphosphonate therapy, n (%) | 39 (25.2) |
| Vitamin D supplement, n (%) | 70 (45.2) |
| Calcium supplement, n (%) | 85 (54.8) |
| Osteoporotic fracture, n (%) | 19/127 (15) |
Values are presented as mean ± SD: standard deviations (SD) or number (%), SD: standard deviations, ANA: anti-nuclear antibody, dsDNA: double-strand deoxyribonucleic acid, ESR: erythrocyte sedimentation rate, SLEDAI: systemic lupus erythematosus disease activity index.
a
Median (Interquatile range).